Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fulgent Genetics ( (FLGT) ) has issued an update.
On May 14, 2026, Fulgent Genetics, Inc. stockholders approved a new 2026 Equity Incentive Plan at the company’s Annual Meeting, replacing the prior omnibus incentive plan and authorizing up to 2,000,000 new shares, plus as many as 1,500,000 additional shares tied to forfeited or cancelled prior awards. This updated plan is expected to shape future equity-based compensation, affecting employee incentives and potential shareholder dilution.
At the same meeting on May 14, 2026, shareholders elected four directors to serve until the 2027 Annual Meeting and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026. Investors also approved, on an advisory basis, the compensation of the company’s named executive officers, signaling broad support for current governance, leadership, and compensation practices.
The most recent analyst rating on (FLGT) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
The score is held back primarily by weak current financial performance (losses and significant cash burn) and bearish technical trends (below major moving averages, negative MACD). Offsetting factors include a very strong, low-debt balance sheet and management’s reiterated FY2026 growth outlook with expected H2 uplift from acquisitions, but profitability and cash-flow recovery remain key execution risks.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics, Inc. operates in the genetics and genomic testing industry, providing diagnostic and therapeutic genetic testing services to healthcare providers, patients, and other stakeholders. The company focuses on leveraging advanced genetic technologies and data analytics to support precision medicine and expand its presence in the broader healthcare and life sciences market.
Average Trading Volume: 650,897
Technical Sentiment Signal: Sell
Current Market Cap: $448.7M
Find detailed analytics on FLGT stock on TipRanks’ Stock Analysis page.